Status:
COMPLETED
Decreased T1 Times and Impaired Myocardial Contractility in Anabolic Androgenic Steroids Users
Lead Sponsor:
University of Sao Paulo General Hospital
Collaborating Sponsors:
Fundação de Amparo à Pesquisa do Estado de São Paulo
Conditions:
Focal Fibrosis
Eligibility:
MALE
18-45 years
Brief Summary
Anabolic androgenic steroids (AAS) abuse may have a toxic on myocardium that could lead to cardiac alterations. Clinical cases reported myocardial fibrosis in AAS users. However, recent studies did no...
Detailed Description
Twenty strength-trained AAS users (AASU) age 29±5 yr, 20 age-matched strength-trained AAS nonusers (AASNU), and 10 sedentary controls (SC) were enrolled. Cardiac structure was assessed by LGE, T1-map...
Eligibility Criteria
Inclusion
- Anabolic androgenic steroids users and Anabolic androgenic steroids nonusers groups had been involved in strength training for at least 2 years;
- Anabolic androgenic steroids users should be self-administering anabolic androgenic steroids in periodic cycles lasting from 8 to 12 weeks for at least 2 years with 2-4 cycles per year;
- All anabolic androgenic steroids users were on a cycle over the course of the study;
- Sedentary control group: sedentary men without cardiovascular disease.
Exclusion
- Smoking;
- Alcohol consumption;
- Use of diuretics and/or antihypertensive medications;
- Liver and kidney disease
Key Trial Info
Start Date :
April 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2017
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03862235
Start Date
April 1 2015
End Date
April 1 2017
Last Update
March 5 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Instituto do Coração do Hospital da Clínicas da Universidade de Sao Paulo
São Paulo, São Paulo, Brazil, 05403-900